World-first gene therapy cures teen with sickle cell disease

Sickle cell is caused by an error in instructions for making haemoglobin, which is packed into RBC

sickle, disease, sickle cell
Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells. Photo: Shutterstock
Press Trust of India London
Last Updated : Mar 06 2017 | 2:04 PM IST
In a world-first, doctors have successfully reversed sickle cell disease in a French teenager using a pioneering treatment to alter his DNA, offering new hope to millions of people with the deadly blood disorder.

Sickle cell disease causes round red blood cells, which carry oxygen around the body, to become shaped like a sickle.

These deformed cells can lock together to block the flow of blood around the body. This can cause intense pain, organ damage and can be fatal.

Also Read

The teenager who received the pioneering treatment had so much internal damage he needed to have his spleen removed and his hips replaced.

He had to undergo hospital blood transfusion to dilute defective blood every month.

However, when he was 13, doctors at the Necker Children's Hospital in Paris, removed his bone marrow - the part of the body that makes blood - and genetically altered it in lab to compensate for the defect in his DNA that caused the disease.

Sickle cell is caused by an error in the instructions for making the protein haemoglobin, which is densely packed into red blood cells.

A virus was used to infect the bone marrow with new, correct instructions. The corrected bone marrow was then put back into the patient.

The therapy has worked for 15 months and the patient is no longer on any medication, doctors said.

"So far the patient has no sign of the disease, no pain, no hospitalisation. He no longer requires a transfusion so we are quite pleased with that," Philippe Leboulch, a professor at the University of Paris, told the BBC News.

"But of course we need to perform the same therapy in many patients to feel confident that it is robust enough to propose it as a mainstream therapy," Leboulch said.

The study was published in the New England Journal of Medicine.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 06 2017 | 1:58 PM IST

Next Story